Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abituzumab for systemic sclerosis-associated interstitial lung disease (Phase II)
2015-005023-11Phase 2Terminated
- Sponsor
- Merck KGaA
- Start
- May 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD) and systemic sclerosis (SSc) comparing Abituzumab with Placebo (2 arms). Primary endpoint: Annual rate of absolute FVC change in volume (mL). Started May 2016; status: terminated.
02
Drugs
abituzumab
03
Conditions
pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2015-005023-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005023-11.